Eton Pharmaceuticals Income Statement 2025-2011 | ETON

Brief overview of financial performance at Eton Pharmaceuticals

The figures are compared over a five-year interval. According to figures from Eton Pharmaceuticals, revenue changed from 39 thousand dollars to 80 million dollars over five years. Overall revenue changed by +204900%, equal to an annualized rate of about 359.6%. The company expanded its revenue base at a high speed.

The five-year change in gross profit reached +10865.7%: from −$397 thousand to $42.7 million. Cost of revenue developed more favorably than sales, supporting gross profitability. The gross margin was −1017.9% at the start and 53.5% at the end. Improving gross profitability strengthens the quality of revenue growth.

The five-year EBITDA result moved by +112%: from −26.8 million dollars to 3.2 million dollars. EBITDA lagged revenue, showing weaker operating momentum. The EBITDA share of revenue changed from −68625.6% to 4%. The business generated more EBITDA from each unit of revenue.

The net financial result changed from −28 million dollars to −4.6 million dollars. The loss narrowed, although sustainable profitability has not yet returned.

Over the period, capitalization shifted from 217 million dollars to 559 million dollars (+157.7%). A large part of future progress may already be reflected in the valuation.

What the figures show

The five-year picture requires weighing both strengths and weaknesses. Key strengths include improving gross profitability, an improving EBITDA margin and a stronger final result. The weaker side of the profile includes limited operating profitability. Investors should continue to monitor margins, costs, and earnings quality.